Pathogenesis and therapy of fungal infectious diseases
Research DescriptionDr. Filler's laboratory focuses on understanding the mechanisms by which the fungi Candida albicans and Aspergillus fumigatus invade and damage cells of hospitalized patients, causing infections that frequently prove fatal, even when employing current therapies. Fungal invasins— the first two of which have been identified by Dr. Filler’s lab—are key to the eventual development of target vaccines. Dr. Filler is a co-founder and scientific advisory board member of NovaDigm Therapeutics, Inc., a company affiliated with LA BioMed that seeks to develop a vaccine against Candida and Staph infections.
- AB, 1979, Dartmouth College, Hanover, NH
- MD, 1983, David Geffen School of Medicine at UCLA, Los Angeles, CA
Recent and/or Significant Publications
- Seidl K, Solis NV, Bayer AS, Hady WA, Ellison S, Klashman MC, Xiong YQ, Filler SG. Divergent Responses of Different Endothelial Cell Types to Infection with Candida albicans and Staphylococcus aureus. PLoS One. 2012;7(6):e39633. Epub 2012 Jun 22.
- Fanning S, Xu W, Solis N, Woolford CA, Filler SG, Mitchell AP. Divergent Targets of Candida albicans Biofilm Regulator Bcr1 In Vitro and In Vivo. Eukaryot Cell. 2012 Jul;11(7):896-904. Epub 2012 Apr 27.
- Solis NV, Filler SG. Mouse model of oropharyngeal candidiasis. Nat Protoc. 2012 Mar 8;7(4):637-42. doi: 10.1038/nprot.2012.011.